January 4, 2024
BME’s Andrew Otte awarded funds to develop a long-lasting biodegradable implant for the treatment of opioid use disorder.
Andrew Otte, PhD is an Emerging Leader in BME. Recently he was awarded $9.85 million from the National Institutes of Health to develop a long-acting biodegradable implant of the drug buprenorphine, which is used for the treatment of opioid use disorder.